Transcription Factors as Therapeutic Targets in Lymphoid Malignancies

REFERENCES

• S.J. Korsmeyer, Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes, Annu. Rev. Immunol., 10: 785–807, 1992.
   PubMed Web of Science ®Google Scholar
• A.T. Look, Oncogenic transcription factors in the human acute leukemias, Science, 278: 1059–1064, 1997.
   PubMed Web of Science ®Google Scholar
• O. Bernard, P. Guglielmi, P. Jonveaux, D. Cherif, S. Gisselbrecht, M. Mauchauffe, R. Berger, C.J. Larsen, and D. Mathieu-Mahul, Two distinct mechanisms for the SCL gene activation in the t(1;14) translocation of T-cell leukemias, Genes Chromosomes Cancer, 1: 194–208, 1990.
   PubMed Web of Science ®Google Scholar
• D.L. Saltman, J.D. Mellentin, S.D. Smith, and M.L. Cleary, Mapping of translocation breakpoints on the short arm of chromosome 19 in acute leukemias by in situ hybridization, Genes Chromosomes Cancer, 2: 259–265, 1990.
   PubMed Web of Science ®Google Scholar
• J.D. Mellentin, C. Murre, T.A. Donlon, P.S. McCaw, S.D. Smith, A.J. Carroll, M.E. McDonald, D. Baltimore, and M.L. Cleary, The gene for enhancer binding proteins E12/E47 lies at the t(1;19) breakpoint in acute leukemias, Science, 246: 379–382, 1989.
   PubMed Web of Science ®Google Scholar
• Poel S. Ziemin-van der, N.R. McCabe, H.J. Gill, R. Espinosa, III, Y. Patel, A. Harden, P. Rubinelli, S.D. Smith, M.M. LeBeau, J.D. Rowley, , et al., Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias, Proc. Natl. Acad. Sci. U.S.A., 88: 10735–10739, 1991.
   Google Scholar
• E. Brownell, H.P. Fell, P.W. Tucker, Kessel A.H. Geurts van, A. Hagemeijer, and N.R. Rice, Regional localization of the human c-rel locus using translocation chromosome analysis, Oncogene, 2: 527–529, 1988.
   Google Scholar
• B. Rayet and C. Gelinas, Aberrant rel/nfkb genes and activity in human cancer, Oncogene, 18: 6938–6947, 1999.
   PubMed Web of Science ®Google Scholar
• E. Cabannes, G. Khan, F. Aillet, R.F. Jarrett, and R.T. Hay, Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha, Oncogene, 18: 3063–3070, 1999.
   PubMed Web of Science ®Google Scholar
• D. Krappmann, F. Emmerich, U. Kordes, E. Scharschmidt, B. Dorken, C. Scheidereit. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells, Oncogene, 18: 943–953, 1999.
   PubMed Web of Science ®Google Scholar
• B. Adams, P. Dorfler, A. Aguzzi, Z. Kozmik, P. Urbanek, I. Maurer-Fogy, and M. Busslinger, Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis, Genes Dev., 6: 1589–1607, 1992.
   PubMed Web of Science ®Google Scholar
• C.G. Mullighan, S. Goorha, I. Radtke, C.B. Miller, E. Coustan-Smith, J.D. Dalton, K. Girtman, S. Mathew, J. Ma, S.B. Pounds, X. Su, C.H. Pui, M.V. Relling, W.E. Evans, S.A. Shurtleff, and J.R. Downing, Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia, Nature, 446: 758–764, 2007.
   PubMed Web of Science ®Google Scholar
• R. Dalla-Favera, M. Bregni, J. Erikson, D. Patterson, R.C. Gallo, and C.M. Croce, Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells, Proc. Natl. Acad. Sci. U.S.A., 79: 7824–7827, 1982.
   PubMed Web of Science ®Google Scholar
• M.H. Kramer, J. Hermans, E. Wijburg, K. Philippo, E. Geelen, J.H. van Krieken, D. de Jong, E. Maartense, E. Schuuring, and P.M. Kluin, Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma, Blood, 92: 3152–3162, 1998.
   PubMed Web of Science ®Google Scholar
• T. Palomero, W.K. Lim, D.T. Odom, M.L. Sulis, P.J. Real, A. Margolin, K.C. Barnes, J. O' Neil, D. Neuberg, A.P. Weng, , et al., NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth, Proc. Natl. Acad. Sci. U.S.A., 103: 18261–18266, 2006.
   PubMed Web of Science ®Google Scholar
• G. Gaidano, P. Ballerini, J.Z. Gong, G. Inghirami, A. Neri, E.W. Newcomb, I.T. Magrath, D.M. Knowles, and R. Dalla-Favera, p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. U.S.A., 88: 5413–5417, 1991.
   PubMed Web of Science ®Google Scholar
• A. Neri, L. Baldini, D. Trecca, L. Cro, E. Polli, and A.T. Maiolo, p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy, Blood, 81: 128–135, 1993.
   PubMed Web of Science ®Google Scholar
• A. Sakashita, T. Hattori, C.W. Miller, H. Suzushima, N. Asou, K. Takatsuki, and H.P. Koeffler, Mutations of the p53 gene in adult T-cell leukemia, Blood, 79: 477–480, 1992.
   PubMed Web of Science ®Google Scholar
• A.P. Weng, A.A. Ferrando, W. Lee, J.P.T. Morris, L.B. Silverman, C. Sanchez-Irizarry, S.C. Blacklow, A.T. Look, and J.C. Aster, Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia, Science, 306: 269–271, 2004.
   PubMed Web of Science ®Google Scholar
• C. Grabher, H. von Boehmer, and A.T. Look, Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia, Nat. Rev. Cancer, 6: 347–359, 2006.
   PubMed Web of Science ®Google Scholar
• A. Sambandam, I. Maillard, V.P. Zediak, L. Xu, R.M. Gerstein, J.C. Aster, W.S. Pear, and A. Bhandoola, Notch signaling controls the generation and differentiation of early T lineage progenitors, Nat. Immunol., 6: 663–670, 2005.
   PubMed Web of Science ®Google Scholar
• S.M. Lehar, J. Dooley, A.G. Farr, and M.J. Bevan, Notch ligands Delta 1 and Jagged1 transmit distinct signals to T-cell precursors, Blood, 105: 1440–1447, 2005.
   PubMed Web of Science ®Google Scholar
• A. Wilson, H.R. MacDonald, and F. Radtke, Notch 1-deficient common lymphoid precursors adopt a B cell fate in the thymus, J. Exp. Med., 194: 1003–1012, 2001.
   PubMed Web of Science ®Google Scholar
• D.J. Izon, J.C. Aster, Y. He, A. Weng, F.G. Karnell, V. Patriub, L. Xu, S. Bakkour, C. Rodriguez, D. Allman, and W.S. Pear, Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch1, Immunity, 16: 231–243, 2002.
   PubMedGoogle Scholar
• J.C. Pui, D. Allman, L. Xu, S. DeRocco, F.G. Karnell, S. Bakkour, J.Y. Lee, T. Kadesch, R.R. Hardy, J.C. Aster, and W.S. Pear, Notch1 expression in early lymphopoiesis influences B versus T lineage determination, Immunity, 11: 299–308, 1999.
   PubMed Web of Science ®Google Scholar
• T.M. Schmitt and J.C. Zuniga-Pflucker, Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro, Immunity, 17: 749–756, 2002.
   PubMed Web of Science ®Google Scholar
• B.H. Ye, G. Cattoretti, Q. Shen, J. Zhang, N. Hawe, R. de Waard, C. Leung, M. Nouri-Shirazi, A. Orazi, R.S. Chaganti, , et al., The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation, Nat. Genet., 16: 161–170, 1997.
   PubMed Web of Science ®Google Scholar
• G. Cattoretti, C.C. Chang, K. Cechova, J. Zhang, B.H. Ye, B. Falini, D.C. Louie, K. Offit, R.S. Chaganti, and R. Dalla-Favera, BCL-6 protein is expressed in germinal-center B cells, Blood, 86: 45–53, 1995.
   PubMed Web of Science ®Google Scholar
• A.L. Shaffer, X. Yu, Y. He, J. Boldrick, E.P. Chan, and L.M. Staudt, BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control, Immunity, 13: 199–212, 2000.
   PubMed Web of Science ®Google Scholar
• R.T. Phan and R. Dalla-Favera, The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells, Nature, 432: 635–639, 2004.
   PubMed Web of Science ®Google Scholar
• S.M. Ranuncolo, J.M. Polo, J. Dierov, M. Singer, T. Kuo, J. Greally, R. Green, M. Carroll, and A. Melnick, Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR, Nat. Immunol., 8: 705–714, 2007.
   PubMedGoogle Scholar
• B.H. Ye, F. Lista, F. Lo Coco, D.M. Knowles, K. Offit, R.S. Chaganti, and R. Dalla-Favera, Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma, Science, 262: 747–750, 1993.
   PubMed Web of Science ®Google Scholar
• G.L. Condorelli, F. Facchiano, M. Valtieri, E. Proietti, L. Vitelli, V. Lulli, K. Huebner, C. Peschle, and C.M. Croce, T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice, Cancer Res., 56: 5113–5119, 1996.
   PubMedGoogle Scholar
• D.A. Dedera, E.K. Waller, D.P. LeBrun, A. Sen-Majumdar, M.E. Stevens, G.S. Barsh, and M.L. Cleary, Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice, Cell, 74: 833–843, 1993.
   PubMed Web of Science ®Google Scholar
• S. Iida, P.H. Rao, M. Butler, P. Corradini, M. Boccadoro, B. Klein, R.S. Chaganti, and R. Dalla-Favera, Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma, Nat. Genet., 17: 226–230, 1997.
   PubMed Web of Science ®Google Scholar
• S. Iida and R. Ueda, Multistep tumorigenesis of multiple myeloma: Its molecular delineation, Int. J. Hematol., 77: 207–212, 2003.
   Google Scholar
• M. Karin, Nuclear factor-kappaB in cancer development and progression, Nature, 441: 431–436, 2006.
   PubMed Web of Science ®Google Scholar
• T. Okamoto, T. Sanda, and K. Asamitsu, NF-kappaB signaling and carcinogenesis, Curr. Pharm. Des., 13: 447–462, 2007.
   PubMed Web of Science ®Google Scholar
• A.A. Ferrando, D.S. Neuberg, J. Staunton, M.L. Loh, C. Huard, S.C. Raimondi, F.G. Behm, C.H. Pui, J.R. Downing, D.G. Gilliland, , et al., Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia, Cancer Cell, 1: 75–87, 2002.
   PubMed Web of Science ®Google Scholar
• B.D. Yu, J.L. Hess, S.E. Horning, G.A. Brown, and S.J. Korsmeyer, Altered Hox expression and segmental identity in Mll-mutant mice, Nature, 378: 505–508, 1995.
   PubMed Web of Science ®Google Scholar
• A.A. Ferrando, S.A. Armstrong, D.S. Neuberg, S.E. Sallan, L.B. Silverman, S.J. Korsmeyer, and A.T. Look, Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: Dominance of HOX dysregulation, Blood, 102: 262–268, 2003.
   PubMed Web of Science ®Google Scholar
• R. Sen and D. Baltimore, Multiple nuclear factors interact with the immunoglobulin enhancer sequences, Cell, 46: 705–716, 1986.
   PubMed Web of Science ®Google Scholar
• C. Kunsch, S.M. Ruben, and C.A. Rosen, Selection of optimal kappaB/Rel DNA-binding motifs: Interaction of both subunits of NF-kappaB with DNA is required for transcriptional activation, Mol. Cell. Biol., 12: 4412–4421, 1992.
   PubMed Web of Science ®Google Scholar
• B.B. Aggarwal and Y. Takada, Pro-apototic and anti-apoptotic effects of tumor necrosis factor in tumor cells. Role of nuclear transcription factor NF-kappaB, Cancer Treat. Res., 126: 103–127, 2005.
   Google Scholar
• C. Chen, L.C. Edelstein, and C. Gelinas, The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L) Mol. Cell. Biol., 20: 2687–2695, 2000.
   PubMed Web of Science ®Google Scholar
• C.Y. Wang, M.W. Mayo, R.G. Korneluk, D.V. Goeddel, and A.S. Baldwin Jr, NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation, Science, 281: 1680–1683, 1998.
   PubMed Web of Science ®Google Scholar
• M. Hinz, D. Krappmann, A. Eichten, A. Heder, C. Scheidereit, and M. Strauss, NF-kappaB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition, Mol. Cell. Biol., 19: 2690–2698, 1999.
   PubMed Web of Science ®Google Scholar
• K. Tozawa, S. Sakurada, K. Kohri, and T. Okamoto, Effects of anti-nuclear factor kappaB reagents in blocking adhesion of human cancer cells to vascular endothelial cells, Cancer Res., 55: 4162–4167, 1995.
   PubMed Web of Science ®Google Scholar
• A. van de Stolpe, E. Caldenhoven, B.G. Stade, L. Koenderman, J.A. Raaijmakers, J.P. Johnson, and P.T. van der Saag, 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter, J. Biol. Chem., 269: 6185–6192, 1994.
   PubMed Web of Science ®Google Scholar
• D. Chilov, E. Kukk, S. Taira, M. Jeltsch, J. Kaukonen, A. Palotie, V. Joukov, and K. Alitalo, Genomic organization of human and mouse genes for vascular endothelial growth factor C, J. Biol. Chem., 272: 25176–25183, 1997.
   Google Scholar
• Q.W. Xie, Y. Kashiwabara, and C. Nathan, Role of transcription factor NF-kappaB/Rel in induction of nitric oxide synthase, J. Biol. Chem., 269: 4705–4708, 1994.
   PubMed Web of Science ®Google Scholar
• V.B. Andela, E.M. Schwarz, J.E. Puzas, R.J. O' Keefe, and R.N. Rosier, Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB, Cancer Res., 60: 6557–6562, 2000.
   Google Scholar
• Y.J. Jung, J.S. Isaacs, S. Lee, J. Trepel, and L. Neckers, IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis, Faseb J., 17: 2115–2117, 2003.
   PubMed Web of Science ®Google Scholar
• M.P. Duyao, A.J. Buckler, and G.E. Sonenshein, Interaction of an NF-kappaB-like factor with a site upstream of the c-myc promoter, Proc. Natl. Acad. Sci. U. S. A., 87: 4727–4731, 1990.
   PubMed Web of Science ®Google Scholar
• T.D. Gilmore, Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel, Oncogene, 18: 6925–6937, 1999.
   PubMed Web of Science ®Google Scholar
• K.M. Wood, M. Roff, and R.T. Hay, Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB, Oncogene, 16: 2131–2139, 1998.
   PubMed Web of Science ®Google Scholar
• R.C. Bargou, F. Emmerich, D. Krappmann, K. Bommert, M.Y. Mapara, W. Arnold, H.D. Royer, E. Grinstein, A. Greiner, C. Scheidereit, and B. Dorken, Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells, J. Clin. Invest., 100: 2961–2969, 1997.
   PubMed Web of Science ®Google Scholar
• U. Kordes, D. Krappmann, V. Heissmeyer, W.D. Ludwig, and C. Scheidereit, Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells, Leukemia, 14: 399–402, 2000.
   PubMed Web of Science ®Google Scholar
• T. Sanda, S. Iida, H. Ogura, K. Asamitsu, T. Murata, K.B. Bacon, R. Ueda, and T. Okamoto, Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitor, Clin. Cancer Res., 11: 1974–1982, 2005.
   PubMed Web of Science ®Google Scholar
• A.C. Bharti, S. Shishodia, J.M. Reuben, D. Weber, R. Alexanian, Raj-S. Vadhan, Z. Estrov, M. Talpaz, and B.B. Aggarwal, Nuclear factor-kappaB and STAT3 are constitutively active in CD138 + cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis, Blood, 103: 3175–3184, 2004.
   PubMed Web of Science ®Google Scholar
• N. Mori, M. Fujii, S. Ikeda, Y. Yamada, M. Tomonaga, D.W. Ballard, and N. Yamamoto, Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells, Blood, 93: 2360–2368, 1999.
   PubMed Web of Science ®Google Scholar
• T. Sanda, K. Asamitsu, H. Ogura, S. Iida, A. Utsunomiya, R. Ueda, and T. Okamoto, Induction of cell death in adult T-cell leukemia cells by a novel IkappaB kinase inhibitor, Leukemia, 20: 590–598, 2006.
   PubMed Web of Science ®Google Scholar
• S. Mathew, V.V. Murty, R. Dalla-Favera, and R.S. Chaganti, Chromosomal localization of genes encoding the transcription factors, c-rel, NF-kappa Bp50, NF-kappa Bp65, and lyt-10 by fluorescence in situ hybridization, Oncogene, 8: 191–193, 1993.
   PubMed Web of Science ®Google Scholar
• J. Houldsworth, S. Mathew, P.H. Rao, K. Dyomina, D.C. Louie, N. Parsa, K. Offit, and R.S. Chaganti, REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma, Blood, 87: 25–29, 1996.
   PubMed Web of Science ®Google Scholar
• P.H. Rao, J. Houldsworth, K. Dyomina, N.Z. Parsa, J.C. Cigudosa, D.C. Louie, L. Popplewell, K. Offit, S.C. Jhanwar, and R.S. Chaganti, Chromosomal and gene amplification in diffuse large B-cell lymphoma, Blood, 92: 234–240, 1998.
   PubMed Web of Science ®Google Scholar
• J.J. Yunis, M.G. Mayer, M.A. Arnesen, D.P. Aeppli, M.M. Oken, and G. Frizzera, bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma, N. Engl. J. Med., 320: 1047–1054, 1989.
   PubMed Web of Science ®Google Scholar
• D. Trecca, L. Guerrini, N.S. Fracchiolla, M. Pomati, L. Baldini, A.T. Maiolo, and A. Neri, Identification of a tumor-associated mutant form of the NF-kappaB RelA gene with reduced DNA-binding and transactivating activities, Oncogene, 14: 791–799, 1997.
   Google Scholar
• N.S. Fracchiolla, L. Lombardi, M. Salina, A. Migliazza, L. Baldini, E. Berti, L. Cro, E. Polli, A.T. Maiolo, and A. Neri, Structural alterations of the NF-kappaB transcription factor lyt-10 in lymphoid malignancies, Oncogene, 8: 2839–2845, 1993.
   PubMed Web of Science ®Google Scholar
• A. Migliazza, L. Lombardi, M. Rocchi, D. Trecca, C.C. Chang, R. Antonacci, N.S. Fracchiolla, P. Ciana, A.T. Maiolo, and A. Neri, Heterogeneous chromosomal aberrations generate 3′ truncations of the NFKB2/lyt-10 gene in lymphoid malignancies, Blood, 84: 3850–3860, 1994.
   PubMed Web of Science ®Google Scholar
• A. Neri, C.C. Chang, L. Lombardi, M. Salina, P. Corradini, A.T. Maiolo, R.S. Chaganti, and R. Dalla-Favera, B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappaB p50, Cell, 67: 1075–1087, 1991.
   PubMed Web of Science ®Google Scholar
• S. Thakur, H.C. Lin, W.T. Tseng, S. Kumar, R. Bravo, F. Foss, C. Gelinas, and A.B. Rabson, Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells, Oncogene, 9: 2335–2344, 1994.
   PubMed Web of Science ®Google Scholar
• C.C. Chang, J. Zhang, L. Lombardi, A. Neri, and R. Dalla-Favera, Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators, Mol. Cell. Biol., 15: 5180–5187, 1995.
   PubMed Web of Science ®Google Scholar
• G. Franzoso, L. Carlson, L. Poljak, E.W. Shores, S. Epstein, A. Leonardi, A. Grinberg, T. Tran, T. Scharton-Kersten, M. Anver, , et al., Mice deficient in nuclear factor (NF)-kappaB/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture, J. Exp. Med., 187: 147–159, 1998.
   PubMed Web of Science ®Google Scholar
• S. Liptay, R.M. Schmid, N.D. Perkins, P. Meltzer, M.R. Altherr, J.D. McPherson, J.J. Wasmuth, and G.J. Nabel, Related subunits of NF-kappaB map to two distinct loci associated with translocations in leukemia, NFKB1 and NFKB2, Genomics, 13: 287–292, 1992.
   PubMed Web of Science ®Google Scholar
• R. Ferrier, R. Nougarede, S. Doucet, B. Kahn-Perles, J. Imbert, and D. Mathieu-Mahul, Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105, Oncogene, 18: 995–1005, 1999.
   PubMedGoogle Scholar
• T.W. McKeithan, H. Ohno, and M.O. Diaz, Identification of a transcriptional unit adjacent to the breakpoint in the 14;19 translocation of chronic lymphocytic leukemia, Genes Chromosomes Cancer, 1: 247–255, 1990.
   PubMed Web of Science ®Google Scholar
• L. Michaux, J. Dierlamm, I. Wlodarska, V. Bours, H. Van den Berghe, and A. Hagemeijer, t(14;19)/BCL3 rearrangements in lymphoproliferative disorders: a review of 23 cases, Cancer Genet. Cytogenet., 94: 36–43, 1997.
   PubMed Web of Science ®Google Scholar
• H. Ohno, G. Takimoto, and T.W. McKeithan, The candidate proto-oncogene BCL3 is related to genes implicated in cell lineage determination and cell cycle control, Cell, 60: 991–997, 1990.
   PubMed Web of Science ®Google Scholar
• S.T. Ong, M.L. Hackbarth, L.C. Degenstein, D.A. Baunoch, J. Anastasi, and T.W. McKeithan, Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice, Oncogene, 16: 2333–2343, 1998.
   PubMed Web of Science ®Google Scholar
• J.Y. Reuther, G.W. Reuther, D. Cortez, A.M. Pendergast, and A.S. Baldwin Jr, A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation, Genes Dev., 12: 968–981, 1998.
   PubMed Web of Science ®Google Scholar
• K. Ohshima, H. Muta, C. Kawasaki, K. Muta, V. Deyev, M. Kanda, Y. Kumano, E.R. Podack, and M. Kikuchi, Bcl10 expression, rearrangement and mutation in MALT lymphoma: Correlation with expression of nuclear factor-kappaB, Int. J. Oncol., 19: 283–289, 2001.
   Google Scholar
• J. Ruland, G.S. Duncan, A. Elia, I. del Barco Barrantes, L. Nguyen, S. Plyte, D.G. Millar, D. Bouchard, A. Wakeham, P.S. Ohashi, and T.W. Mak, Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure, Cell, 104: 33–42, 2001.
   PubMed Web of Science ®Google Scholar
• R. Horie, M. Watanabe, T. Ishida, T. Koiwa, S. Aizawa, K. Itoh, M. Higashihara, M.E. Kadin, and T. Watanabe, The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma, Cancer Cell, 5: 353–364, 2004.
   PubMed Web of Science ®Google Scholar
• S.S. Mir, B.W. Richter, and C.S. Duckett, Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells, Blood, 96: 4307–4312, 2000.
   PubMed Web of Science ®Google Scholar
• T. Suzuki, H. Hirai, and M. Yoshida, Tax protein of HTLV-1 interacts with the Rel homology domain of NF-kappaB p65 and c-Rel proteins bound to the NF-kappaB binding site and activates transcription, Oncogene, 9: 3099–3105, 1994.
   PubMedGoogle Scholar
• M.J. Yin, L.B. Christerson, Y. Yamamoto, Y.T. Kwak, S. Xu, F. Mercurio, M. Barbosa, M.H. Cobb, and R.B. Gaynor, HTLV-I Tax protein binds to MEKK1 to stimulate IkappaB kinase activity and NF-kappaB activation, Cell, 93: 875–884, 1998.
   PubMed Web of Science ®Google Scholar
• G. Xiao, M.E. Cvijic, A. Fong, E.W. Harhaj, M.T. Uhlik, M. Waterfield, and S.C. Sun, Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: Evidence for the involvement of IKKalpha, EMBO J., 20: 6805–6815, 2001.
   PubMed Web of Science ®Google Scholar
• N. Hironaka, K. Mochida, N. Mori, M. Maeda, N. Yamamoto, and S. Yamaoka, Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells, Neoplasia, 6: 266–278, 2004.
   PubMed Web of Science ®Google Scholar
• X. Jiang, N. Takahashi, N. Matsui, T. Tetsuka, and T. Okamoto, The NF-kappaB activation in lymphotoxin beta receptor signaling depends on the phosphorylation of p65 at serine 536, J. Biol. Chem., 278: 919–926, 2003.
   PubMed Web of Science ®Google Scholar
• J.L. Pomerantz and D. Baltimore, Two pathways to NF-kappaB, Mol. Cell, 10: 693–695, 2002.
   PubMed Web of Science ®Google Scholar
• H. Ichikawa, Y. Takada, A. Murakami, and B.B. Aggarwal, Identification of a novel blocker of I kappaB alpha kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF-kappaB-regulated gene products, J. Immunol., 174: 7383–7392, 2005.
   PubMedGoogle Scholar
• A.C. Bharti, N. Donato, S. Singh, and B.B. Aggarwal, Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappaB and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis, Blood, 101: 1053–1062, 2003.
   PubMed Web of Science ®Google Scholar
• Y. Li, F. Ahmed, S. Ali, P.A. Philip, O. Kucuk, and F.H. Sarkar, Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells, Cancer Res., 65: 6934–6942, 2005.
   PubMed Web of Science ®Google Scholar
• C.M. Lin, S.T. Huang, Y.C. Liang, M.S. Lin, C.M. Shih, Y.C. Chang, T.Y. Chen, and C.T. Chen, Isovitexin suppresses lipopolysaccharide-mediated inducible nitric oxide synthase through inhibition of NF-kappaB in mouse macrophages, Planta Med., 71: 748–753, 2005.
   PubMed Web of Science ®Google Scholar
• A.G. Bowie and L.A. O' Neill, Vitamin C inhibits NF-kappaB activation by TNF via the activation of p38 mitogen-activated protein kinase, J. Immunol., 165: 7180–7188, 2000.
   PubMed Web of Science ®Google Scholar
• M.A. Fiedler, K. Wernke-Dollries, and J.M. Stark, Inhibition of TNF-alpha-induced NF-kappaB activation and IL-8 release in A549 cells with the proteasome inhibitor MG-132, Am. J. Respir. Cell. Mol. Biol., 19: 259–268, 1998.
   PubMed Web of Science ®Google Scholar
• K. Ozaki, H. Takeda, H. Iwahashi, S. Kitano, and S. Hanazawa, NF-kappaB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells, FEBS Lett., 410: 297–300, 1997.
   PubMed Web of Science ®Google Scholar
• T. Hideshima, D. Chauhan, P. Richardson, C. Mitsiades, N. Mitsiades, T. Hayashi, N. Munshi, L. Dang, A. Castro, V. Palombella, J. Adams, and K.C. Anderson, NF-kappaB as a therapeutic target in multiple myeloma, J. Biol. Chem., 277: 16639–16647, 2002.
   PubMed Web of Science ®Google Scholar
• C. Brostjan, J. Anrather, V. Csizmadia, G. Natarajan, and H. Winkler, Glucocorticoids inhibit E-selectin expression by targeting NF-kappaB and not ATF/c-Jun, J. Immunol., 158: 3836–3844, 1997.
   PubMed Web of Science ®Google Scholar
• A. Hilgendorff, H. Muth, B. Parviz, A. Staubitz, W. Haberbosch, H. Tillmanns, and H. Holschermann, Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int. J. Clin. Pharmacol. Ther., 41: 397–401, 2003.
   PubMed Web of Science ®Google Scholar
• J.P. Yang, J.P. Merin, T. Nakano, T. Kato, Y. Kitade, and T. Okamoto, Inhibition of the DNA-binding activity of NF-kappaB by gold compounds in vitro, FEBS Lett., 361: 89–96, 1995.
   PubMed Web of Science ®Google Scholar
• K.E. Traber, H. Okamoto, C. Kurono, M. Baba, C. Saliou, T. Soji, L. Packer, and T. Okamoto, Anti-rheumatic compound aurothioglucose inhibits tumor necrosis factor-alpha-induced HIV-1 replication in latently infected OM10.1 and Ach2 cells, Int. Immunol., 11: 143–150, 1999.
   Google Scholar
• J.A. Keifer, D.C. Guttridge, B.P. Ashburner, and A.S. Baldwin Jr., Inhibition of NF-kappaB activity by thalidomide through suppression of IkappaB kinase activity, J. Biol. Chem., 276: 22382–22387, 2001.
   PubMed Web of Science ®Google Scholar
• T. Hideshima, P. Richardson, D. Chauhan, V.J. Palombella, P.J. Elliott, J. Adams, and K.C. Anderson, The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells, Cancer Res., 61: 3071–3076, 2001.
   PubMed Web of Science ®Google Scholar
• P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, R. Alexanian, , et al., A phase 2 study of bortezomib in relapsed, refractory myeloma, N. Engl. J. Med., 348: 2609–2617, 2003.
   PubMed Web of Science ®Google Scholar
• T. Murata, M. Shimada, S. Sakakibara, T. Yoshino, H. Kadono, T. Masuda, M. Shimazaki, T. Shintani, K. Fuchikami, K. Sakai, , et al., Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1, Bioorg. Med. Chem. Lett., 13: 913–918, 2003.
   PubMed Web of Science ®Google Scholar
• T. Murata, M. Shimada, H. Kadono, S. Sakakibara, T. Yoshino, T. Masuda, M. Shimazaki, T. Shintani, K. Fuchikami, K.B. Bacon, , et al., Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: Improvement of in vitro activity. Bioorg. Med. Chem. Lett., 14: 4013–4017, 2004.
   PubMed Web of Science ®Google Scholar
• N. Mori, Y. Yamada, S. Ikeda, Y. Yamasaki, K. Tsukasaki, Y. Tanaka, M. Tomonaga, N. Yamamoto, and M. Fujii, Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells, Blood, 100: 1828–1834, 2002.
   PubMed Web of Science ®Google Scholar
• K. Umezawa and C. Chaicharoenpong, Molecular design and biological activities of NF-kappaB inhibitors, Mol. Cells, 14: 163–167, 2002.
   PubMed Web of Science ®Google Scholar
• R. Ahmad, D. Raina, C. Meyer, S. Kharbanda, and D. Kufe, Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179, J. Biol. Chem., 281: 35764–35769, 2006.
   PubMed Web of Science ®Google Scholar
• P. Chambon, A decade of molecular biology of retinoic acid receptors, FASEB J., 10: 940–954, 1996.
   PubMed Web of Science ®Google Scholar
• M.F. Boehm, L. Zhang, L. Zhi, M.R. McClurg, E. Berger, M. Wagoner, D.E. Mais, C.M. Suto, J.A. Davies, R.A. Heyman, , et al., Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells, J. Med. Chem., 38: 3146–3155, 1995.
   PubMed Web of Science ®Google Scholar
• L. Nagy, V.A. Thomazy, G.L. Shipley, L. Fesus, W. Lamph, R.A. Heyman, R.A. Chandraratna, and P.J. Davies, Activation of retinoid X receptors induces apoptosis in HL-60 cell lines, Mol. Cell. Biol., 15: 3540–3551, 1995.
   PubMed Web of Science ®Google Scholar
• C.B. Stephensen, R. Rasooly, X. Jiang, M.A. Ceddia, C.T. Weaver, R.A. Chandraratna, and R.P. Bucy, Vitamin A enhances in vitro Th2 development via retinoid X receptor pathway, J. Immunol., 168: 4495–4503, 2002.
   PubMed Web of Science ®Google Scholar
• R. Rasooly, G.U. Schuster, J.P. Gregg, J.H. Xiao, R.A. Chandraratna, and C.B. Stephensen, Retinoid x receptor agonists increase bcl2a1 expression and decrease apoptosis of naive T lymphocytes, J. Immunol., 175: 7916–7929, 2005.
   PubMed Web of Science ®Google Scholar
• C.B. Stephensen, A.D. Borowsky, and K.C. Lloyd, Disruption of Rxra gene in thymocytes and T lymphocytes modestly alters lymphocyte frequencies, proliferation, survival and T helper type 1/type 2 balance, Immunology, 121: 484–498, 2007.
   Google Scholar
• N. Engedal, A. Ertesvag, and H.K. Blomhoff, Survival of activated human T lymphocytes is promoted by retinoic acid via induction of IL-2, Int. Immunol., 16: 443–453, 2004.
   PubMed Web of Science ®Google Scholar
• D. Mucida, Y. Park, G. Kim, O. Turovskaya, I. Scott, M. Kronenberg, and H. Cheroutre, Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid, Science, 317: 256–260, 2007.
   PubMed Web of Science ®Google Scholar
• Q. Chen and A.C. Ross, Inaugural article: Vitamin A and immune function: retinoic acid modulates population dynamics in antigen receptor and CD38-stimulated splenic B cells, Proc. Natl. Acad. Sci. U.S.A., 102: 14142–14149, 2005.
   Google Scholar
• C. Gratas, M.L. Menot, C. Dresch, and C. Chomienne, Retinoid acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells, Leukemia, 7: 1156–1162, 1993.
   PubMed Web of Science ®Google Scholar
• T.R. Breitman, S.E. Selonick, and S.J. Collins, Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid, Proc. Natl. Acad. Sci. U.S.A., 77: 2936–2940, 1980.
   PubMed Web of Science ®Google Scholar
• M. Ponzoni, P. Bocca, V. Chiesa, A. Decensi, V. Pistoia, L. Raffaghello, C. Rozzo, and P.G. Montaldo, Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation, Cancer Res., 55: 853–861, 1995.
   PubMed Web of Science ®Google Scholar
• X.P. Lu, A. Fanjul, N. Picard, M. Pfahl, D. Rungta, K. Nared Hood, B. Carter, J. Piedrafita, S. Tang, and E. Fabbrizio, Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo, Nat. Med., 3: 686–690, 1997.
   PubMed Web of Science ®Google Scholar
• Y.H. Chen, P. Desai, R.T. Shiao, D. Lavelle, A. Haleem, and J. Chen, Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites, Blood, 87: 314–323, 1996.
   PubMed Web of Science ®Google Scholar
• T. Sanda, T. Kuwano, S. Nakao, S. Iida, T. Ishida, H. Komatsu, K. Shudo, M. Kuwano, M. Ono, and R. Ueda, Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis, Leukemia, 19: 901–909, 2005.
   Google Scholar
• R. Dolcetti, P. Zancai, R. Cariati, and M. Boiocchi, In vitro effects of retinoids on the proliferation and differentiation features of Epstein-Barr virus-immortalized B lymphocytes, Leuk. Lymphoma., 29: 269–281, 1998.
   PubMed Web of Science ®Google Scholar
• T. Yamaguchi, Y. Maeda, S. Ueda, Y. Hijikata, Y. Morita, J.I. Miyatake, M. Matsuda, and A. Kanamaru, Dichotomy of all-trans retinoic acid inducing signals for adult T-cell leukemia, Leukemia, 19: 1010–1017, 2005.
   PubMed Web of Science ®Google Scholar
• C. Zhang and M. Duvic, Treatment of cutaneous T-cell lymphoma with retinoids, Dermatol. Ther., 19: 264–271, 2006.
   PubMed Web of Science ®Google Scholar
• P. Zancai, J. Dal Col, S. Piccinin, M. Guidoboni, R. Cariati, S. Rizzo, M. Boiocchi, R. Maestro, and R. Dolcetti, Retinoic acid stabilizes p27Kip1 in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45Skp2 and Cks1 proteins, Oncogene, 24: 2483–2494, 2005.
   Google Scholar
• A.H. Rook, M. Kubin, F.E. Fox, Z. Niu, M. Cassin, B.R. Vowels, S.L. Gottleib, E.C. Vonderheid, S.R. Lessin, and G. Trinchieri, The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma, Ann. N.Y. Acad. Sci., 795: 310–318, 1996.
   PubMed Web of Science ®Google Scholar
• L. Meunier, K. Bohjanen, J.J. Voorhees, and K.D. Cooper, Retinoic acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and CD11c, a beta 2 integrin critically involved in T-cell activation, J. Invest. Dermatol., 103: 775–779, 1994.
   Google Scholar
• M. Duvic, K. Hymes, P. Heald, D. Breneman, A.G. Martin, P. Myskowski, C. Crowley, and R.C. Yocum, Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II–III trial results, J. Clin. Oncol., 19: 2456–2471, 2001.
   PubMed Web of Science ®Google Scholar
• N. Sidell, T. Taga, T. Hirano, T. Kishimoto, and A. Saxon, Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors, J. Immunol., 146: 3809–3814, 1991.
   PubMed Web of Science ®Google Scholar
• A. Ogata, N. Nishimoto, Y. Shima, K. Yoshizaki, and T. Kishimoto, Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction, Blood, 84: 3040–3046, 1994.
   PubMed Web of Science ®Google Scholar
• Y.H. Chen, D. Lavelle, J. DeSimone, S. Uddin, L.C. Platanias, and M. Hankewych, Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1) Blood, 94: 251–259, 1999.
   PubMed Web of Science ®Google Scholar
• K. Koskela, T.T. Pelliniemi, K. Pulkki, and K. Remes, Treatment of multiple myeloma with all-trans retinoic acid alone and in combination with chemotherapy: a phase I/II trial, Leuk. Lymphoma, 45: 749–754, 2004.
   PubMed Web of Science ®Google Scholar
• T. Sanda, S. Iida, S. Kayukawa, and R. Ueda, Induction of class II major histocompatibility complex expression in human multiple myeloma cells by retinoid, Haematologica, 92: 115–120, 2007.
   Google Scholar
• K. Takagi, M. Suganuma, H. Kagechika, K. Shudo, M. Ninomiya, Y. Muto, and H. Fujiki, Inhibition of ornithine decarboxylase induction by retinobenzoic acids in relation to their binding affinities to cellular retinoid-binding proteins, J. Cancer Res. Clin. Oncol., 114: 221–224, 1988.
   PubMedGoogle Scholar
• Y. Hashimoto, H. Kagechika, and K. Shudo, Expression of retinoic acid receptor genes and the ligand-binding selectivity of retinoic acid receptors (RAR's) Biochem Biophys Res Commun, 166: 1300–1307, 1990.
   PubMed Web of Science ®Google Scholar
• T. Tobita, A. Takeshita, K. Kitamura, K. Ohnishi, M. Yanagi, A. Hiraoka, T. Karasuno, M. Takeuchi, S. Miyawaki, R. Ueda, T. Naoe, and R. Ohno, Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid, Blood, 90: 967–973, 1997.
   PubMed Web of Science ®Google Scholar
• P. Silacci, A. Mottet, V. Steimle, W. Reith, and B. Mach, Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA, J. Exp. Med., 180: 1329–1336, 1994.
   PubMed Web of Science ®Google Scholar
• N. Ghosh, I. Gyory, G. Wright, J. Wood, and K.L. Wright, Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells, J. Biol. Chem., 276: 15264–15268, 2001.
   Google Scholar
• K.C. Anderson, Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions, Exp. Hematol., 35: 155–162, 2007.
   PubMed Web of Science ®Google Scholar
• T. Hideshima, C. Mitsiades, G. Tonon, P.G. Richardson, and K.C. Anderson, Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets, Nat. Rev. Cancer, 7: 585–598, 2007.
   PubMed Web of Science ®Google Scholar
• S. Minucci and P.G. Pelicci, Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nat. Rev. Cancer, 6: 38–51, 2006.
   PubMed Web of Science ®Google Scholar
• B.D. Strahl and C.D. Allis, The language of covalent histone modifications, Nature, 403: 41–45, 2000.
   PubMed Web of Science ®Google Scholar
• B.M. Turner, Cellular memory and the histone code, Cell, 111: 285–291, 2002.
   PubMed Web of Science ®Google Scholar
• R. Claus and M. Lubbert, Epigenetic targets in hematopoietic malignancies, Oncogene, 22: 6489–6496, 2003.
   PubMed Web of Science ®Google Scholar
• J. Arts, S. de Schepper, and K. Van Emelen, Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics, Curr. Med. Chem., 10: 2343–2350, 2003.
   PubMed Web of Science ®Google Scholar
• C.S. Mitsiades, N.S. Mitsiades, C.J. McMullan, V. Poulaki, R. Shringarpure, T. Hideshima, M. Akiyama, D. Chauhan, N. Munshi, X. Gu, , et al., Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications, Proc. Natl. Acad. Sci. U.S.A., 101: 540–545, 2004.
   PubMed Web of Science ®Google Scholar
• C. Zhang, V. Richon, X. Ni, R. Talpur, and M. Duvic, Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action, J. Invest. Dermatol., 125: 1045–1052, 2005.
   PubMed Web of Science ®Google Scholar
• T. Sanda, T. Okamoto, Y. Uchida, H. Nakagawa, S. Iida, S. Kayukawa, T. Suzuki, T. Oshizawa, T. Suzuki, N. Miyata, and R. Ueda, Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells, Leukemia, 2007, [E pub ahead of print].
   Google Scholar
• C. Hubbert, A. Guardiola, R. Shao, Y. Kawaguchi, A. Ito, A. Nixon, M. Yoshida, X.F. Wang, and T.P. Yao, HDAC6 is a microtubule-associated deacetylase, Nature, 417: 455–458, 2002.
   PubMed Web of Science ®Google Scholar
• A. Insinga, S. Monestiroli, S. Ronzoni, R. Carbone, M. Pearson, G. Pruneri, G. Viale, E. Appella, P. Pelicci, and S. Minucci, Impairment of p53 acetylation, stability and function by an oncogenic transcription factor, EMBO. J., 23: 1144–1154, 2004.
   PubMed Web of Science ®Google Scholar
• O.R. Bereshchenko, W. Gu, and R. Dalla-Favera, Acetylation inactivates the transcriptional repressor BCL6, Nat. Genet., 32: 606–613, 2002.
   PubMed Web of Science ®Google Scholar
• P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, , et al., Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors, J. Biol. Chem., 280: 26729–26734, 2005.
   PubMed Web of Science ®Google Scholar
• J. Luo, F. Su, D. Chen, A. Shiloh, and W. Gu, Deacetylation of p53 modulates its effect on cell growth and apoptosis, Nature, 408: 377–381, 2000.
   PubMed Web of Science ®Google Scholar
• Y. Zhao, S. Lu, L. Wu, G. Chai, H. Wang, Y. Chen, J. Sun, Y. Yu, W. Zhou, Q. Zheng, , et al., Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1) Mol. Cell. Biol., 26: 2782–2790, 2006.
   PubMed Web of Science ®Google Scholar
• W.K. Kelly and P.A. Marks, Drug insight: histone deacetylase inhibitors–development of the new targeted anticancer agent suberoylanilide hydroxamic acid, Nat. Clin. Pract. Oncol., 2: 150–157, 2005.
   PubMedGoogle Scholar
• P.A. Marks, Discovery and development of SAHA as an anticancer agent, Oncogene, 26: 1351–1356, 2007.
   PubMed Web of Science ®Google Scholar
• L. Huang, Y. Sowa, T. Sakai, and A.B. Pardee, Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites, Oncogene, 19: 5712–5719, 2000.
   PubMed Web of Science ®Google Scholar
• V.M. Richon, T.W. Sandhoff, R.A. Rifkind, and P.A. Marks, Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation, Proc. Natl. Acad. Sci. U.S.A., 97: 10014–10019, 2000.
   PubMed Web of Science ®Google Scholar
• M.J. Peart, G.K. Smyth, R.K. van Laar, D.D. Bowtell, V.M. Richon, P.A. Marks, A.J. Holloway, and R.W. Johnstone, Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors, Proc. Natl. Acad. Sci. U.S.A., 102: 3697–3702, 2005.
   PubMed Web of Science ®Google Scholar
• T. Hideshima, J.E. Bradner, J. Wong, D. Chauhan, P. Richardson, S.L. Schreiber, and K.C. Anderson, Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma, Proc. Natl. Acad. Sci. U.S.A., 102: 8567–8572, 2005.
   PubMed Web of Science ®Google Scholar
• J.S. Ungerstedt, Y. Sowa, W.S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang, and P.A. Marks, Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors, Proc. Natl. Acad. Sci. U.S.A., 102: 673–678, 2005.
   PubMed Web of Science ®Google Scholar
• O.A. O'Connor, M.L. Heaney, L. Schwartz, S. Richardson, R. Willim, B. MacGregor-Cortelli, T. Curly, C. Moskowitz, C. Portlock, S. Horwitz, , et al., Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies, J. Clin. Oncol., 24: 166–173, 2006.
   PubMed Web of Science ®Google Scholar
• M. Duvic, R. Talpur, X. Ni, C. Zhang, P. Hazarika, C. Kelly, J.H. Chiao, J.F. Reilly, J.L. Ricker, V.M. Richon, and S.R. Frankel, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood, 109: 31–39, 2007.
   PubMed Web of Science ®Google Scholar
• W.K. Kelly, O.A. O'Connor, L.M. Krug, J.H. Chiao, M. Heaney, T. Curley, B. MacGregore-Cortelli, W. Tong, J.P. Secrist, L. Schwartz, , et al., Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer, J. Clin. Oncol., 23: 3923–3931, 2005.
   PubMed Web of Science ®Google Scholar
• Q.C. Ryan, D. Headlee, M. Acharya, A. Sparreboom, J.B. Trepel, J. Ye, W.D. Figg, K. Hwang, E.J. Chung, A. Murgo, , et al., Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma, J. Clin. Oncol., 23: 3912–3922, 2005.
   PubMed Web of Science ®Google Scholar
• L.M. Golub, H.M. Lee, M.E. Ryan, W.V. Giannobile, J. Payne, and T. Sorsa, Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms, Adv. Dent. Res., 12: 12–26, 1998.
   PubMedGoogle Scholar
• T. Suzuki, Y. Nagano, A. Kouketsu, A. Matsuura, S. Maruyama, M. Kurotaki, H. Nakagawa, and N. Miyata, Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates, J. Med. Chem., 48: 1019–1032, 2005.
   PubMedGoogle Scholar
• L.W. Ellisen, J. Bird, D.C. West, A.L. Soreng, T.C. Reynolds, S.D. Smith, and J. Sklar, TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms, Cell, 66: 649–661, 1991.
   PubMed Web of Science ®Google Scholar
• J. O'Neil, J. Grim, P. Strack, S. Rao, D. Tibbitts, C. Winter, J. Hardwick, M. Welcker, J.P. Meijerink, R. Pieters, , et al., FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to {gamma}-secretase inhibitors, J. Exp. Med., 204: 1813–1824, 2007.
   PubMed Web of Science ®Google Scholar
• W.S. Pear, J.C. Aster, M.L. Scott, R.P. Hasserjian, B. Soffer, J. Sklar, and D. Baltimore, Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles, J. Exp. Med., 183: 2283–2291, 1996.
   PubMed Web of Science ®Google Scholar
• D. Shimizu, T. Taki, A. Utsunomiya, H. Nakagawa, K. Nomura, Y. Matsumoto, K. Nishida, S. Horiike, and M. Taniwaki, Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma, Int. J. Hematol., 85: 212–218, 2007.
   Google Scholar
• L. Fu, N. Nara, and S. Tohda, Involvement of Notch signaling in myelodysplastic syndrome, Leuk. Res., 31: 1160–1161, 2007.
   Google Scholar
• S.A. Armstrong and A.T. Look. Molecular genetics of acute lymphoblastic leukemia, J. Clin. Oncol., 23: 6306–6315, 2005.
   PubMed Web of Science ®Google Scholar
• E. Sicinska, I. Aifantis, L. Le Cam, W. Swat, C. Borowski, Q. Yu, A.A. Ferrando, S.D. Levin, Y. Geng, H. von Boehmer, and P. Sicinski, Requirement for cyclin D3 in lymphocyte development and T cell leukemias, Cancer Cell, 4: 451–461, 2003.
   PubMed Web of Science ®Google Scholar
• L.J. Beverly, D.W. Felsher, and A.J. Capobianco, Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression, Cancer Res., 65: 7159–7168, 2005.
   PubMed Web of Science ®Google Scholar
• S.M. Chan, A.P. Weng, R. Tibshirani, J.C. Aster, and P.J. Utz, Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia, Blood, 110: 278–286, 2007.
   PubMed Web of Science ®Google Scholar
• H.D. Lewis, M. Leveridge, P.R. Strack, C.D. Haldon, J. O'Neil, H. Kim, A. Madin, J.C. Hannam, A.T. Look, N. Kohl, , et al., Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem. Biol., 14: 209–219, 2007.
   PubMed Web of Science ®Google Scholar
• M.E. Fortini, Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling, Nat. Rev. Mol. Cell Biol., 3: 673–684, 2002.
   PubMed Web of Science ®Google Scholar